<DOC>
	<DOC>NCT01800695</DOC>
	<brief_summary>This study is evaluating the safety and pharmacokinetics of ABT-414 in subjects with glioblastoma multiforme.</brief_summary>
	<brief_title>Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>1. Glioblastoma Multiforme (GBM) 2. 70 or above on Karnofsky Performance Status 3. Adequate bone marrow function 4. Recurrent GBM per RANO criteria 5. Subjects must have confirmed EGFR amplification by central lab 1. For Subjects with recurrent GBM in Arm B, subject has received prior treatment with bevacizumab, nitrosourea, or has secondary GBM 2. For Subjects with recurrent GBM in Arm C, subject has received prior treatment with bevacizumab, or has secondary GBM 3. Allergies to temozolomide, dacarbazine, IgG containing agents 4. Anticancer treatment 28 days prior to study Day 1, except in Arm B expanded cohort temozolomide therapy is allowed 5. Subjects that have had more than one disease recurrence</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>GBM</keyword>
</DOC>